ESR1 and non-small cell lung carcinoma: To determine whether the antiestrogen effect of the ER antagonist fulvestrant can be enhanced by CLI-095 or vice versa, we treated the NSCLC cell lines A549 and H1793 in different groups with E2, E2 and fulvestrant, E2 and CLI-095 or a combination of the drugs.